1. Home
  2. MESO vs NRDS Comparison

MESO vs NRDS Comparison

Compare MESO & NRDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • NRDS
  • Stock Information
  • Founded
  • MESO 2004
  • NRDS 2009
  • Country
  • MESO Australia
  • NRDS United States
  • Employees
  • MESO N/A
  • NRDS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • NRDS EDP Services
  • Sector
  • MESO Health Care
  • NRDS Technology
  • Exchange
  • MESO Nasdaq
  • NRDS Nasdaq
  • Market Cap
  • MESO 1.2B
  • NRDS 994.4M
  • IPO Year
  • MESO N/A
  • NRDS 2021
  • Fundamental
  • Price
  • MESO $14.63
  • NRDS $13.00
  • Analyst Decision
  • MESO Strong Buy
  • NRDS Buy
  • Analyst Count
  • MESO 4
  • NRDS 6
  • Target Price
  • MESO $13.50
  • NRDS $17.00
  • AVG Volume (30 Days)
  • MESO 552.8K
  • NRDS 489.9K
  • Earning Date
  • MESO 08-28-2024
  • NRDS 02-12-2025
  • Dividend Yield
  • MESO N/A
  • NRDS N/A
  • EPS Growth
  • MESO N/A
  • NRDS N/A
  • EPS
  • MESO N/A
  • NRDS N/A
  • Revenue
  • MESO $5,902,000.00
  • NRDS $637,500,000.00
  • Revenue This Year
  • MESO $66.05
  • NRDS $14.44
  • Revenue Next Year
  • MESO $348.27
  • NRDS $12.90
  • P/E Ratio
  • MESO N/A
  • NRDS N/A
  • Revenue Growth
  • MESO N/A
  • NRDS 4.90
  • 52 Week Low
  • MESO $1.61
  • NRDS $10.10
  • 52 Week High
  • MESO $19.15
  • NRDS $17.30
  • Technical
  • Relative Strength Index (RSI)
  • MESO 64.37
  • NRDS 43.09
  • Support Level
  • MESO $12.20
  • NRDS $12.42
  • Resistance Level
  • MESO $19.15
  • NRDS $13.64
  • Average True Range (ATR)
  • MESO 0.98
  • NRDS 0.60
  • MACD
  • MESO 0.37
  • NRDS -0.14
  • Stochastic Oscillator
  • MESO 48.93
  • NRDS 26.73

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides onsumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. They get revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.

Share on Social Networks: